-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

741 Spatially Resolved Single-Cell Transcriptomics of T Cells in Follicular Lymphoma Reveals Distinct Immune Ecosystems

Program: Oral and Poster Abstracts
Type: Oral
Session: 621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Indolent Lymphomas
Hematology Disease Topics & Pathways:
Research, Adult, Translational Research, Lymphomas, B Cell lymphoma, Bioinformatics, Diseases, Immunology, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Study Population, Human, Imaging, Omics technologies, Pathology
Monday, December 9, 2024: 11:00 AM

Yoshiaki Abe, MD, PhD1*, Junko Zenkoh2*, Akinori Kanai2*, Daisuke Ikeda3*, Daisuke Kaji, MD, PhD4*, Sawa Aya5*, Ryota Matsuoka, MD, PhD6*, Kei Asayama7*, Rikako Tabata, M.D.8*, Ryota Ishii, Ph.D.9*, Manabu Fujisawa10*, Makishima Kenichi11*, Sakurako Suma, MD, PhD12*, Yasuhito Suehara, MD, PhD13*, Keiichiro Hattori, MD, PhD1*, Tatsuhiro Sakamoto, MD, PhD1*, Hidekazu Nishikii, MD, PhD13, Chikashi Yoshida14*, Hiroko Bando15*, Ayako Suzuki2*, Yasunori Ota, MD, PhD16*, Yoshihito Otsuka, Ph.D.17*, Daisuke Matsubara7*, Kosei Matsue, M.D., Ph.D.8, Shigeru Chiba, MD, PhD1*, Shigeru Chiba, MD, PhD1*, Christian Steidl, MD, PhD18, Yutaka Suzuki, PhD19* and Mamiko Sakata-Yanagimoto1*

1Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
2The University of Tokyo, Kashiwa, Japan
3Kameda Medical Center, Kamaogawa, Japan
4Department of Hematology, Toranomon Hospital, Tokyo, Japan
5Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, Tsukuba, Japan
6Department of Pathology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
7University of Tsukuba, Tsukuba, Japan
8Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan
9Department of Biostatistics, Institute of Medicine,, University of Tsukuba, Tsukuba, ibaraki, Japan
10Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada
11University of Tsukuba Hospital, Tsukuba, Japan
12Department of Hematology, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
13Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
14NHO Mito Medical Center, Mito, Japan
15Department of Breast and Endocrine Surgery, University of Tsukuba, Tsukuba, Japan
16Department of Pathology, The Institute of Medical Science Research Hospital, The University of Tokyo, Tokyo, Japan
17Department of Laboratory Medicine, Kameda Medical Center, Chiba, Japan
18Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
19Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan

Background: Recent studies have shown that the extent of T-cell infiltration strongly correlates with a low frequency of early relapse in patients with follicular lymphoma (FL). This suggests that a deeper understanding of T-cell heterogeneity and biology could lead to the development of novel FL biomarkers. Our previous single-cell RNA sequencing (scRNA-seq) analysis (Abe et al. ASH 2023) revealed significant heterogeneity in T cells, particularly in follicular T cell components in FL. This study aimed to elucidate the spatial characteristics of T cells in FL, focusing on the follicular T cell subsets relevant to FL biology.

Methods: We performed a spatially resolved single-cell transcriptomic analysis of six formalin-fixed paraffin-embedded samples of newly diagnosed FL using the Xenium In Situ system. We used a custom gene panel comprising 289 genes curated from the differentially expressed genes detected in the scRNA-seq analysis of various immune and stromal cells in FL. After DAPI-based cell segmentation, single-cell transcriptome data were integrated and subjected to unsupervised clustering analysis to reproduce the results of the scRNA-seq analysis. The spatially smoothed chemokine gene density was calculated using the kernel-smoothing method. Multiplex digital spatial profiling (MDSP) was performed on 242 FL samples from three cohorts to validate the Xenium analysis findings.

Results: We analyzed the transcriptome data from 516,657 cells detected using Xenium. Unsupervised clustering analysis detected T cell components, in addition to malignant (Bmalig) and non-malignant B cells, monocytes/dendritic cells, plasma cells, and stromal cells, including endothelial cells. Sub-clustering analysis detected T cell subsets annotated as lymphoma follicular regulatory (LTFR) and CD4 (LTFC4) or CD8 (LTFC8) lymphoma follicular cytotoxic T cells in our previous scRNA-seq analysis, as well as conventional T cell subsets, including follicular helper (TFH), regulatory (Treg), and cytotoxic (Tct) T cells. The transcriptional features of these subsets were consistent with their scRNA-seq profiles. Remarkably, the LTFR and LTFC cells were preferentially observed within and at the edges of neoplastic follicles (NFs), respectively. The minimum distance from LTFR cells to NFs or Bmalig cells was shorter than that from Treg cells.Similarly, compared to Tct cells, LTFC cells were localized closer to NFs or Bmalig cells. Additionally, compared to LTFC cells, LTFR cells tended to be closer to NFs or Bmalig cells. The spatially smoothed densities of CXCL13 and CCL19 were relatively high in the NFs and T-cell zones, respectively, as reported previously. We also confirmed that the CXCL13 and CCL19 densities were the highest at the coordinate points of TFH and naïve T cells, respectively. Among the non-TFH T cell populations, the highest CXCL13 and lowest CCL19 densities were detected at the coordinates of LTFR cells, whereas the joint density of CXCL13 and CCL19, which estimated their overlap, was the highest at LTFC cell positions, supporting the distribution patterns of these cell subsets. The spatial and distance relationships depicted using the MDSP echoed those suggested by the Xenium analysis. Correlation analysis of cell localization identified remarkably high correlations between LTFR and TFH cells and between LTFC4 and LTFC8 cells. Cellular neighborhood analysis revealed that LTFR and TFH cells formed distinct cellular neighborhoods, suggesting that LTFR cells specifically suppressed TFH cells activity. Additionally, the LTFC4 and LTFC8 cells formed neighborhoods, consistent with their biased distribution at the edge regions of the NFs. Literature-based upstream regulator and Xenium spatial gene density analyses suggested that interleukin-21 (IL-21) was the most relevant inducer of LTFR, LTFC4, and LTFC8 cells. Consistently, the phenotypes of these cells were reproduced in cell culture in the presence of IL-21, suggesting that the IL-21-predominant FL microenvironment, enriched with activated TFH cells, induced these non-TFH cell subsets and elicited anti-tumorigenic immunity.

Conclusions: Our spatially resolved single-cell analysis of T cells revealed the presence and characteristic distribution patterns of distinct follicular T cell subsets in FL. This approach highlights the self-regulatory immune ecosystems that may underlie FL biology and clinical behavior.

Disclosures: Kaji: Chugai Pharmaceutical Co.: Honoraria; Genmab: Honoraria; Eisai Co.: Honoraria; Bristol Myers Squibb K.K.: Honoraria; AstraZeneca: Honoraria; AbbVie GK.: Honoraria; SymBio Pharmaceuticals: Honoraria; Sanofi K.K.: Honoraria; Pfizer Japan Inc.: Honoraria; Ono Pharmaceutical Co.: Honoraria; Meiji Seika Pharma Co.: Honoraria; Janssen Pharmaceutical KK.: Honoraria; Asahi Kasei Pharma Co.: Honoraria; Takeda Pharmaceutical Co.: Honoraria. Yoshida: Novartis Pharmaceuticals: Honoraria; Bristol Myers Squibb: Research Funding. Matsue: Janssen pharmaceutica: Research Funding; Sanofi: Research Funding; Bristol-Myers Squibb K.K: Research Funding. Chiba: Thyas: Research Funding; Astellas: Research Funding; Kyowa Kirin: Research Funding; Chugai Pharmaceutical: Honoraria; Bayer Pharma: Honoraria; Eisai Co., Ltd.: Honoraria. Chiba: Thyas: Research Funding; Astellas: Research Funding; Kyowa Kirin: Research Funding; Chugai Pharmaceutical: Honoraria; Bayer Pharma: Honoraria; Eisai Co., Ltd.: Honoraria. Steidl: EISAI: Consultancy; Seattle Genetics: Consultancy; AbbVie: Consultancy; Bayer: Consultancy; Bristol Myers Squibb: Research Funding; Epizyme: Research Funding; Trillium Therapeutics Inc: Research Funding. Sakata-Yanagimoto: LSI Medience: Patents & Royalties; Chugai Pharma, Eisai, Bristol Myers Squibb: Research Funding; Chugai Pharma, Eisai, Meiji Seika, Janssen, AbbVie, Astellas, Kyowa Kirin, Takeda, Nippon Kayaku, MSD, Nippon Shinyaku: Speakers Bureau.

*signifies non-member of ASH